临床 试验
- BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)条件:淋巴瘤分子:Zanubrutinib
- A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma条件:淋巴瘤分子:Zanubrutinib
- BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies条件:淋巴瘤, 白血病, 骨髓瘤分子:Zanubrutinib
- A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL条件:白血病, 淋巴瘤分子:Zanubrutinib
- A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)条件:淋巴瘤分子:Zanubrutinib
- Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)条件:淋巴瘤分子:Zanubrutinib
- Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma条件:淋巴瘤分子:Zanubrutinib
- Study of Evaluate Efficacy and Safety of BGB-3111 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)条件:淋巴瘤分子:Zanubrutinib
- Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma条件:白血病, 淋巴瘤分子:Zanubrutinib
- A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma条件:淋巴瘤分子:Zanubrutinib